Australia

Breaking the Design Barrier: X-Design Evolves into Zawa, Launching a Dedicated Creative AI Agent for Branding

From "democratizing design" to "systematizing growth," Zawa's new "Zero to Wow" philosophy redefines the future of visual automation for SMBs and local merchants. SYDNEY, March 18, 2026 /PRNewswire/ -- X-Design, the pioneering platform that made professional design accessible to everyone, today ...

2026-03-19 03:39 6175

Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal

HIGHLIGHTS * Oral presentation on key results from the Co-PSMA (NCT06907641 )[1] Investigator-Initiated Trial (IIT) was delivered by ProfLouise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the ...

2026-03-17 21:01 7617

Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer

LISMORE, Australia, March 15, 2026 /PRNewswire/ -- Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment f...

2026-03-16 09:43 3979

Vmake Video Enhancer Introduces "AI 4K+": Setting a New Standard in AI Video Enhancement

SYDNEY, March 10, 2026 /PRNewswire/ -- Vmake recently announced a major upgrade to VmakeVideo Enhancer , introducing AI 4K+, a new enhancement mode designed to deliver sharper, more natural-looking upscales for creators and businesses who need premium video qualit...

2026-03-11 01:00 5922

Registrational Phase III AMPLIFY trial: Target number of participants achieved

SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III A...

2026-03-10 21:02 7675

Faybl launches in US, offering RIAs chance to shape the future of AI-powered advice

* Faybl delivers proven efficiency gains of up to 70 percent in support of US advice industry that is struggling for capacity * Faybl has grown Australian user base by 50 percent; already testing V2 in home market * Anthony Lipp announced as new Adviser * Faybl's leadership team will be at...

2026-03-10 20:00 5154

Westpac to change the format of its long-term USD funding

SYDNEY, March 5, 2026 /PRNewswire/ -- Westpac Banking Corporation ("Westpac") today announced its intention to voluntarily deregister from the United States Securities and Exchange Commission (the "SEC") by filing a Form 15F with the SEC as early asMay 2026. Upon filing the Form 15F, Westpac's re...

2026-03-06 01:59

Firmable Raises $14m Series A to Take AI-Native Sales Platform Global

MELBOURNE, Australia, March 2, 2026 /PRNewswire/ -- Firmable, Asia-Pacific's leading AI (artificial intelligence) sales platform, has raised$14 million in Series A funding led by Airtree, with participation from existing investors. The funding will support Firmable's expansion tothe United States...

2026-03-03 00:30 7575

Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial

Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...

2026-02-27 04:34 9142

GTM.io Launches Operating Partner Model to Close the Go-to-Market Execution Gap

Built for scaling B2B technology companies seeking stronger pipeline, more consistent revenue execution and sustainable customer expansion. SYDNEY, Feb. 25, 2026 /PRNewswire/ -- GTM.io today announced the formal launch of its Operating Partner model, designed to address a persi...

2026-02-26 04:00 4685

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS * Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. * The study was led by Prof Louise Emmett at St Vincent's Hospital Sydney, and the abstract was accepted for oral presentation at the upcoming European Association of Urology (...

2026-02-16 22:03 11320

Delonix Bioworks Announces IND Clearance for DX-104, a Novel Engineered MenB OMV Vaccine Candidate, in China and Australia

SHANGHAI, Feb. 6, 2026 /PRNewswire/ -- Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines,recently announced that its Group B meningococcal (MenB) vaccine candidate, DX-104, has received Investigational New Drug (IND) clearance fromChina's Natio...

2026-02-06 20:00 8194

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, to...

2026-01-30 21:00 11238

Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), today provided a clinical update from its ongoing Phase1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC)....

2026-01-27 21:00 10302

Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.

AUCKLAND, New Zealand, Jan. 21, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, theMyriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in theJournal of Trauma and Injury. MASTRR is t...

2026-01-23 03:13 6242

Hydrexia to Provide Hydrogen Application Solution to Toyota

SIDNEY, Jan. 22, 2026 /PRNewswire/ -- Hydrexia Pty Ltd, the wholly owned subsidiary of Hydrexia Holding Limited (Hydrexia), a leading hydrogen technology solution provider, announced today that it has secured an order to provide The Toyota Motor Corporation Australia Ltd (TMCA) with a number o...

2026-01-22 23:00 9274

GAC Enters Australia with AION V, M8 PHEV and EMZOOM; Launches Australian Local Strategy to Build a Benchmark Market in the South Pacific

SYDNEY, Jan. 21, 2026 /PRNewswire/ -- On November 18, 2025, GAC hosted its brand and new model launch ceremony inSydney, officially unveiling its Australia Local Strategy—"GAC: Growing Australian Confidence"—the localized implementation of the company's global "One GAC 2.0" strategy. One of the ...

2026-01-22 09:51 5038

Life's Moments App Launches Worldwide on iPhone and Android -- Turning Scattered Photos, Family Memories and Pet Moments into One Organized Family Tree

All Your Family's Memories… Finally Organized ADELAIDE, Australia, Jan. 20, 2026 /PRNewswire/ -- Life's Moments App today announced its global launch on iPhone and Android, giving families and pet owners an intuitive way to capture, store and organize photos, videos, milestones and important rec...

2026-01-20 21:07 6647

SECuRE trial to continue with no modifications to protocol following Safety Review Committee meeting

HIGHLIGHTS * Following an interim data review of the Cohort Expansion Phase (Phase II) of the SECuRE trial, the Safety Review Committee (SRC) confirms the trial will continue with no modifications to the protocol. Patient population * With the SECuRE trial continuing to recruit, a total of n...

2026-01-15 22:02 8821

Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) today announced that its Chief Executive Officer,John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will ...

2026-01-08 22:00 9554
123456 ... 41